IntoCell has announced a MoU with US-based contract development and manufacturing organisatioXcellon Biologics.

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in ...

D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150.

Bayer and BI have reported broadly similar efficacy outcomes for sevabertinib and Hernexeos in HER2-mutant NSCLC.

A sales probe from Organon's board has found evidence of wholesaler sales malpractice, resulting in Ali's resignation and a ...

While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.

Helex has raised $3.5m in a seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for kidney ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

The FDA's draft guidance is supposed to cut the cost and time-associated burden of biosimilar development, despite a mixed ...